burst-forming uniteerythroid; and colony-forming unitegranulocyte, erythrocyte, monocyte, megakaryocyte). Flow cytometry measured %HPCs in peripheral blood; plasma granulocyte colony-stimulating factor (G-CSF) levels were measured via enzyme-linked immunosorbent assay. Data were analyzed by one-way analysis of variance followed by the Tukey multiple comparison test.
1.

Introduction
Persistent injury-associated anemia and increased susceptibility to infection [1, 2] are manifestations of the bone marrow (BM) dysfunction observed after severe injury with significant clinical ramifications. In a rodent model of lung contusion (LC) alone, this dysfunction is manifested as a reduction in BM cellularity and growth of hematopoietic progenitor cells (HPCs) within the BM itself and mobilization of HPCs to the periphery with an associated rise in plasma granulocyte colony-stimulating factor (G-CSF) early after injury; however, rats recovered within 7 d [3, 4] . When animals undergo lung contusion following hemorrhagic shock (LCHS), BM dysfunction is both more acutely marked and persists for >1 wk [3, 4] .
Mesenchymal stem cells (MSCs) are a type of multipotent cell with multiple immunomodulatory and paracrine functions that are essential to maintain the BM microenvironment and support hematopoiesis [5e7]. They have been investigated in several disease states, such as graft-versus-host disease, aplastic anemia, and myocardial infarction, as a potential cellular therapy to expedite healing and restore homeostasis [8e10] .
We have previously investigated the role of these cells in lung healing [11] ; however, we have not examined their role in treating the BM dysfunction that ensues after injury. We hypothesize that treatment of rats undergoing combined LCHS with MSCs given early after resuscitation can reverse injuryassociated BM dysfunction. Furthermore, we hypothesize that this protection occurs via a systemic effect by altering the plasma in shocked animals such that it is no longer suppressive to BM cells in vitro.
2.
Materials and methods
Experimental groups
Male rats (n ¼ 5e6 per group) were assigned to experimental groups as follows: LC alone, LC plus MSCs (LC þ MSCs), LCHS, and LC followed by HS plus MSCs (LCHS þ MSCs). A control naive group of uninjured animals undergoing daily handling was also used. On day 7, rats were sacrificed and BM and blood collected.
Animals
Male SpragueeDawley rats weighing between 250 and 350 g (Charles River, Wilmington, MA) were maintained according to the recommendations of the Guide for the Care 
LC model
After intraperitoneal administration of sodium pentobarbital (50 mg/kg), a 12-mm metal plate was secured to the rat's right axilla and a percussive nail gun (Craftsman 968514 Stapler; Sears Brands, Chicago, IL) was used to induce a unilateral LC.
HS model
As previously described [12] , immediately after LC, rats in the LCHS and LCHS þ MSC groups underwent cannulation of the right internal jugular vein and right femoral artery with polyethylene (PE-50; Becton Dickinson and Co, Sparks, MD) and Silastic (Dow Corning Corp, Midland, MI) tubing, respectively. To prevent clotting, all tubing was flushed with 10 U/mL of heparinized saline. The femoral artery catheter was then connected to a continuous blood pressure monitoring device for measurement of mean arterial pressure (MAP) and heart rate. Animals were bled to an MAP of 30e35 mm Hg for 45 min; additional blood was withdrawn or reinfused as needed to maintain MAP within range. Temperature was maintained at approximately 37 C with the use of an electric heating pad placed under the surgical platform. After the completion of the shock period, shed blood was reinfused at a rate of 1 mL/min.
MSC culture
As previously described [13] 
MSC injection
A previously prepared suspension of 5 Â 10 6 MSCs in 1-mL of IMDM was infused via the previously cannulated right internal jugular vein for >5 min, beginning within 10 min of injury in the LC and LC þ MSC groups or within 10 min of return of shed blood in the groups undergoing HS.
BM cellularity
BM cells were harvested from the right femur to determine cellularity and establish cell culture. An 18-gauge needle was inserted into the femur and BM was aspirated into 1-mL IMDM. Cells were suspended, stained with 0.4% trypan blue, and hemocytometer was used to determine total viable cell count.
BM HPC cultures
Growth of HPCs from the BM was assessed by culturing colony-forming unitegranulocyte, erythrocyte, monocyte,
megakaryocyte (CFU-GEMM), burst-forming uniteerythroid (BFU-E), and colony-forming uniteerythroid (CFU-E). A stock solution of BM cells was prepared according to the cellularity to reach a concentration of 1 Â 10 6 cells/mL of IMDM. A solution of IMDM supplemented with 30% fetal bovine serum, 2% bovine serum albumin, rat growth factor, 1% methylcellulose, 2 Â 10 À4 mol/L 2-mercaptoethanol, penicillin, streptomycin, and glutamine was prepared and 1.5 Â 10 5 cells added to it. All cultures were plated in duplicate. Those plates growing BFU-E and CFU-E were further supplemented with 1.3 U/mL rhEpo and 6 U/mL rhIL-3. Plates growing CFU-GEMM were supplemented with 3 U/mL recombinant human granulocyte-macrophage colony-stimulating factor. Cultures were incubated at 37 C in 5% CO 2 incubator. CFU-E colonies were counted on day 7, BFU-E on day 14, and CFU-GEMM on day 17 by an observer blinded to sample origin.
Cultures with experimental plasma
BM was collected from naive rats, and cellularity and stock solutions were prepared as described previously. Again, cells were plated in duplicate. Although all BM cells came from naive rats, cells were plated with the addition of 5% vol/vol of plasma from rats in one of the following experimental groups: unmanipulated control, LCHS, or LCHS þ MSC. An additional control group consisting of naive BM cells incubated with media alone was used for comparison (naive). Plasma was obtained after sacrifice on day 7 after injury. As previously mentioned, cultures were counted after the appropriate number of days of incubation according to colony type by a blinded observer.
Flow cytometry for HPCs
Blood samples were obtained via direct cardiac puncture using a 10-mL heparinized syringe at the time of sacrifice. A well established, single-platform enumeration method was used to determine the frequency of CD71þ, CD117þ HPCs within unfractionated blood samples. Briefly, 100 mL whole blood was labeled with 10 mL of BD Pharmingen mouse anti-rat CD71 antibody conjugated with fluorescein isothiocyanate and 10 mL of BD Pharmingen rat anti-mouse CD117 (c-Kit) antibody conjugated to phycoerythrin (BD Biosciences, Franklin Lakes, NJ) for 30 min. Erythrocytes were then lysed with ammonium chloride in a 37 C humidified 5% CO 2 incubator for 10 min.
After lysis, cells were centrifuged at 300 Â g for 5 min and supernatant was discarded before washing three times. After fixation with BD Cytofix solution (BD Biosciences), cells were analyzed using BD FACSCalibur flow cytometer (BD Biosciences) equipped with CellQuest software (BD Biosciences) with an event count of 50,000 each run.
Plasma G-CSF levels
A commercial enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN) run in duplicate was used to determine plasma G-CSF levels. Briefly, 50 mL of assay diluent RD1-54 and 50 mL of standard, control, or sample were added to wells precoated with polyclonal anti-mouse G-CSF. Plate was covered and after 2 h of incubation at room temperature, wells were aspirated and washed a total of five times. One hundred microliters of mouse G-CSF conjugate was then added to each well before another 2 h of covered incubation. Plate was again washed a total of five times before adding100 mL substrate solution to each well and a 30 min of dark incubation. One hundred microliters of stop solution was then added to each well, mixed gently, and plate was read using 450e540 nm wavelength correction.
Reagents
Bovine serum albumin and 2-mercaptoethanol were purchased from SigmaeAldrich (St. Louis, MO). Methylcellulose was purchased from Stemcell Technologies (Vancouver, Canada). Fetal bovine serum, IMDM, glutamine, penicillin, streptomycin, and trypan blue were obtained from Invitrogen (Carlsbad, CA). All cytokines rhEpo, rhIL-3, and recombinant human granulocytemacrophage colony-stimulating factor were purchased from R&D Systems (Minneapolis, MN). Sodium pentobarbital was purchased from B&B Pharmacy (Bellflower, CA) and heparin was obtained from Hospira Inc (Lakefront, IL).
Statistical analysis
All data are expressed as the mean AE standard deviation. Statistical analyses were performed using one-way analysis of variance followed by the TukeyeKramer multiple comparison posttest or the Student t-test with GraphPad Prism (version 4.0; GraphPad Software, Inc, La Jolla, San Diego, CA). Results were considered significant if *P < 0.05 versus LC or **P < 0.05 versus LCHS.
Results
Effect of MSCs on BM cellularity
There is no statistically significant difference in BM cellularity in those animals undergoing either unilateral LC alone or LC þ MSC compared with naive levels at 7 d. Seven days after LCHS there is a 13% decrease in BM cellularity compared with naive (197 AE 19 versus 225 AE 6; P < 0.05). The addition of MSCs to animals undergoing LCHS resulted in a 9.7% increase in cellularity compared with LCHS alone, returning cellularity to naive levels (217 AE 4 versus 197 AE 19; P < 0.05; Fig. 1A ).
Effect of MSCs on BM HPC cultures
There is no significant change in growth of any of the HPC types examined 7 d after either LC alone or LC þ MSCs. There is a 22% decrease in CFU-GEMM 7 d after LCHS (28 AE 1 versus 35 AE 1; P < 0.05). The addition of MSCs at the time of resuscitation results in a 16% increase in CFU-GEMM growth, returning it to naive levels (33 AE 1 versus 28 AE 1; Fig. 1B ). At 7 d after LCHS there are 30% and 24% decreases in BFU-E and CFU-E, respectively (50 AE 3 versus 68 AE 3 and 60 AE 3 versus 77 AE 4, respectively; P < 0.05). When animals undergoing LCHS were given MSCs, there were 33% and 30% increases in BFU-E and CFU-E, respectively, again returning colony growth to naive levels (70 AE 1 versus 50 AE 3 and 81 AE 1 versus 60 AE 3, respectively; P < 0.05; Fig. 1C and D) .
3.3.
Effect of MSCs on mobilization of HPCs and plasma G-CSF
Seven days after either LC or LCHS there was no statistically significant difference in HPC mobilization ( Fig. 2A) . Furthermore, the addition of MSCs to LC or LCHS groups did not significantly alter the percentage of HPCs circulating in the peripheral blood. However, plasma G-CSF levels remained increased in those animals undergoing LCHS (12.3 AE 3.6 versus 4.7 AE 2.1; P < 0.05). The addition of MSCs returned G-CSF to naive levels (5.4 AE 1.7 versus 4.7 AE 2.1; P > 0.05; Fig. 2B ).
Effect of experimental plasma on naive BM HPC growth in vitro
There was no difference in CFU-E colony counts in naive BM incubated with media alone and naive BM incubated with 5% vol/vol naive plasma (unmanipulated control). When naive BM cells were incubated with 5% plasma from 7-d animals undergoing LCHS, there was a 30% decrease in CFU-E colony growth compared with naive cells incubated with media alone (57.3 AE 2.6 versus 77.4 AE 4.0; P < 0.001). When naive BM cells were incubated with plasma from animals undergoing LCHS with MSCs after resuscitation, suppression was no longer observed (76.1 AE 2.3 versus 77.4 AE 4.0; P > 0.05; Fig. 3 ).
Discussion
BM dysfunction has long been described after severe injury and HS [1, 2] . In human trauma patients, this dysfunction manifests as both disordered growth of HPCs within the BM itself and increased mobilization of these cells to the periphery [2] . In critically injured patients, this dysfunction manifests as a persistent posttraumatic anemia [14] . In the present study, we examine the effects of MSCs in a wellestablished rat model of combined LCHS resulting in BM dysfunction [3, 4] . We demonstrate that treatment with MSCs immediately after resuscitation results in a return of HPC colony growth within the BM and plasma G-CSF levels to naive within 7 d after injury. Furthermore, treatment with MSCs alters the composition of the plasma such that it is no longer suppressive to HPC colony growth in culture.
MSCs are multipotent cells that have been shown to have myriad paracrine and immunomodulatory functions [15] . These cells are considered to constitute an essential part of the BM microenvironment and are important in supporting hematopoietic homeostasis via the secretion of various cytokines and expressing adhesion molecules involved in hematopoietic stem cell homing [5e7]. Although MSCs have not previously been examined in the treatment of posttraumatic BM dysfunction, their effects on the BM have been studied in the context of aplastic anemia, lupus-associated anemia, and in cotransplantation with MSCs as part of a BM transplant [16e18]. Wu et al. [19] treated a cohort of 21 patients with severe aplastic anemia with MSCs cotransplanted with haploidentical hematopoietic stem cells and demonstrated sustained hematopoietic engraftment without an increase in graft-versus-host disease. MSCs have also been shown to improve cell counts in patients with refractory cytopenia secondary to systemic lupus erythematosus [17] . Although these studies report dramatic results in severely ill patient populations, the exact mechanism of action of MSCs largely remains unknown. Our data demonstrate that a single dose of intravenous MSCs given immediately after resuscitation in LCHS animals resulted in increase in BM cellularity and HPC growth to naive levels by 7 d after injury. The ability of MSCs to modulate and support the BM microenvironment may be protective against the dysfunction observed in the setting of combined LCHS.
Other manifestations of BM dysfunction after LCHS at 7 d include HPCs returning from the periphery to the BM, despite modest increase in plasma G-CSF levels. Increases in plasma G-CSF have been shown in severely injured trauma patients and this increase is associated with a significant increase in peripheral HPCs [20] . Petit et al. [21] reported that G-CSF within the BM modulates the release of HPC from their stromal attachments via elastase-dependent degradation, allowing mobilization of these cells to the periphery. Clinically, G-CSF is often given to mobilize both hematopoietic and MSCs to the periphery in preparation for BM transplantation. The current data shows a relationship between exogenous MSC administration and an endogenous decrease in G-CSF. It appears that treatment with MSCs hastens the return of G-CSF to naive levels, possibly indicating an earlier return of HPCs from the periphery and swifter recovery of BM homeostasis after injury.
Although it is possible that MSCs have local effects within the BM niche, we hypothesized that their ability to protect the BM against posttraumatic dysfunction is because of their systemic effect after a global ischemiaereperfusion event. Plasma from trauma patients has been shown to inhibit HPC colony growth in vitro up to 2 wk after injury [22] . Consistent with prior findings, we show that plasma from animals that had undergone LCHS significantly suppressed growth of CFU-E, whereas plasma from animals receiving MSCs did not. Although these data indicate that MSCs modulate the plasma, reversing this in vitro suppressive effect, it is unknown what components of the plasma are altered. Nevertheless, this finding indicates that the effects of MSCs go beyond the local BM niche.
Our data establish the protective role of MSCs in BM dysfunction observed after trauma and HS. MSCs given immediately after resuscitation reverse BM dysfunction observed 7 d after injury by returning BM cellularity and HPC colony growth to naive levels. This protection is associated with a decrease in plasma G-CSF and the return of HPCs from the periphery. Furthermore, we demonstrate that MSCs modulate the suppressive effect of plasma on BM cells in vitro, indicating a systemic effect of these cells. Furthermore, studies are necessary to elucidate the mechanisms by which MSCs function on both a local level within the BM niche and systemically. Additionally, the optimal dosing of MSCs and therapeutic window for administration remain to be defined. The use of MSCs as a cellular therapy after severe trauma with HS may provide great benefit in the treatment of BM dysfunction and its resultant anemia.
